Factor Xa generation by computational modeling: An additional discriminator to thrombin generation evaluation

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Brummel Ziedins, Kathleen E ^a   Orfeo, Thomas ^a   Gissel, Matthew ^a   Mann, Kenneth G ^a   Rosendaal, Frits R ^b  

^a UNIVERSITY OF VERMONT   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; ORAL CONTRACEPTIVE AGENT; PROTHROMBIN; THROMBIN; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; AGE; ARTICLE; BODY MASS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; RISK FACTOR; SEX DIFFERENCE; SIMULATION; THROMBOSIS; AGED; BIOLOGICAL MODEL; BLOOD CLOTTING; CASE CONTROL STUDY; COMPARATIVE STUDY; COMPUTER SIMULATION; METABOLISM; MIDDLE AGED;

AGED; ANTITHROMBINS; BLOOD COAGULATION; BODY MASS INDEX; CASE-CONTROL STUDIES; COMPUTER SIMULATION; FACTOR XA; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RISK FACTORS; THROMBIN;

EID: 84855671103     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029178     Document Type: Article

References (35)

1. Berntorp E, Salvagno GL, (2008) Standardization and clinical utility of thrombin-generation assays. Semin Thromb Hemost 34: 670-682.
2. Hirsh J, O'Donnell M, Eikelboom JW, (2007) Beyond unfractionated heparin and warfarin: current and future advances. Circulation 116: 552-560.
3. Jesty J, Silverberg SA, (1979) Kinetics of the tissue factor-dependent activation of coagulation Factors IX and X in a bovine plasma system. J Biol Chem 254: 12337-12345.
4. Butenas S, van 't Veer C, Mann KG, (1997) Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases. J Biol Chem 272: 21527-21533.
5. Mann KG, Krishnaswamy S, Lawson JH, (1992) Surface-dependent hemostasis. Semin Hematol 29: 213-226.
6. Lawson JH, Mann KG, (1991) Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation. J Biol Chem 266: 11317-11327.
7. Ahmad SS, Rawala-Sheikh R, Walsh PN, (1992) Components and assembly of the factor X activating complex. Semin Thromb Hemost 18: 311-323.
8. Rand MD, Lock JB, van 't Veer C, Gaffney DP, Mann KG, (1996) Blood clotting in minimally altered whole blood. Blood 88: 3432-3445.
9. Brummel KE, Paradis SG, Butenas S, Mann KG, (2002) Thrombin functions during tissue factor-induced blood coagulation. Blood 100: 148-152.
10. Eikelboom JW, Weitz JI, (2010) New anticoagulants. Circulation 121: 1523-1532.
11. Orfeo T, Butenas S, Brummel-Ziedins KE, Mann KG, (2005) The tissue factor requirement in blood coagulation. J Biol Chem 280: 42887-42896.
12. de Visser MC, Poort SR, Vos HL, Rosendaal FR, Bertina RM, (2001) Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis. Thromb Haemost 85: 1011-1017.
13. Hockin MF, Jones KC, Everse SJ, Mann KG, (2002) A model for the stoichiometric regulation of blood coagulation. J Biol Chem 277: 18322-18333.
14. Butenas S, Orfeo T, Gissel MT, Brummel KE, Mann KG, (2004) The significance of circulating factor IXa in blood. J Biol Chem 279: 22875-22882.
15. Brummel-Ziedins K, Vossen CY, Rosendaal FR, Umezaki K, Mann KG, (2005) The plasma hemostatic proteome: thrombin generation in healthy individuals. J Thromb Haemost 3: 1472-1481.
16. Brummel-Ziedins KE, Gissel M, Francis C, Queenan J, Mann KG, (2009) The effect of high circulating estradiol levels on thrombin generation during in vitro fertilization. Thromb Res 124: 505-507.
17. Orfeo T, Butenas S, Brummel-Ziedins KE, Gissel M, Mann KG, (2010) Anticoagulation by factor Xa inhibitors. J Thromb Haemost 8: 1745-1753.
18. van der Meer FJ, Koster T, Vandenbroucke JP, Briet E, Rosendaal FR, (1997) The Leiden Thrombophilia Study (LETS). Thromb Haemost 78: 631-635.
19. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR, (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345: 152-155.
20. Brummel-Ziedins KE, Orfeo T, Jenny NS, Everse SJ, Mann KG, Blood Coagulation and Fibrinolysis. In: Greer JP, Foerster J, Rodgers GM, Paraskevas F, Glader B, Arber DA, editors. Wintrobe's Clinical Hematology Philadelphia Lippincott Williams & Wilkins pp. 528-619.
21. Brummel-Ziedins KE, Vossen CY, Butenas S, Mann KG, Rosendaal FR, (2005) Thrombin generation profiles in deep venous thrombosis. J Thromb Haemost 3: 2497-2505.
22. Brummel-Ziedins K, Undas A, Orfeo T, Gissel M, Butenas S, Zmudka K, et al. (2008) Thrombin generation in acute coronary syndrome and stable coronary artery disease: dependence on plasma factor composition. J Thromb Haemost 6: 104-110.
23. Brummel-Ziedins KE, Orfeo T, Rosendaal FR, Undas A, Rivard GE, et al. (2009) Empirical and theoretical phenotypic discrimination. J Thromb Haemost 7 (Suppl 1): 181-186.
24. Gissel M, Undas A, Slowik A, Mann KG, Brummel-Ziedins KE, (2010) Plasma factor and inhibitor composition contributes to thrombin generation dynamics in patients with acute or previous cerebrovascular events. Thromb Res 126: 262-269.
25. Undas A, Gissel M, Kwasny-Krochin B, Gluszko P, Mann KG, et al. (2010) Thrombin generation in rheumatoid arthritis: dependence on plasma factor composition. Thromb Haemost 104: 224-230.
26. Weitz JI, (2010) New oral anticoagulants in development. Thromb Haemost 103: 62-70.
27. Barrett YC, Wang Z, Frost C, Shenker A, (2010) Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 104: 1263-1271.
28. Harris LF, Castro-Lopez V, Jenkins PV, O'Donnell JS, Killard AJ, (2011) Comparison of a fluorogenic anti-FXa assay with a central laboratory chromogenic anti-FXa assay for measuring LMWH activity in patient plasmas. Thromb Res in press.
29. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR, (2009) The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 339: b2921.
30. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP, (1995) Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346: 1593-1596.
31. Heinemann LA, Dinger JC, Assmann A, Minh TD, (2010) Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10 years after the third-generation "pill scare". Contraception 81: 401-407.
32. Sehovic N, Smith KP, (2010) Risk of venous thromboembolism with drospirenone in combined oral contraceptive products. Ann Pharmacother 44: 898-903.
33. Segers O, van Oerle R, ten Cate H, Rosing J, Castoldi E, (2010) Thrombin generation as an intermediate phenotype for venous thrombosis. Thromb Haemost 103: 114-122.
34. Brummel-Ziedins KE, Pouliot RL, Mann KG, (2004) Thrombin generation: phenotypic quantitation. J Thromb Haemost 2: 281-288.
35. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, et al. (1999) Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 81: 680-683.